Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACMSD | Q8TDX5 | 18/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | PRNP | P04156 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.48 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23892639 | 0.91 | ACMSD (0.84) | ACMSDCYP2C19MEN1PRNPKMT2A | |
| SCHEMBL31053402 | 0.86 | ACMSD (1.00) | ACMSDCYP2C19MEN1USP2PRNP | |
| SCHEMBL17550085 | 0.86 | ACMSD (1.00) | ACMSDCYP2C19MEN1USP2PRNP | |
| SCHEMBL17548426 | 0.85 | ACMSD (0.74) | ACMSDCYP2C19MEN1USP2PRNP | |
| SCHEMBL17548488 | 0.85 | ACMSD (1.00) | ACMSDMEN1POLBKMT2A | |
| SCHEMBL17553535 | 0.83 | ACMSD (0.71) | ACMSDCYP2C19MEN1USP2PRNP | |
| SCHEMBL17548491 | 0.81 | ACMSD (1.00) | ACMSDMEN1USP2PKMKMT2A | |
| SCHEMBL31053416 | 0.77 | ACMSD (0.85) | ACMSDCYP2C19MEN1USP2PRNP | |
| SCHEMBL26847147 | 0.77 | ACMSD (0.85) | ACMSDCYP2C19MEN1USP2PRNP | |
| SCHEMBL23849892 | 0.77 | ACMSD (0.85) | ACMSDCYP2C19MEN1USP2PRNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023227666-A1 | PYRIMIDINONE COMPOUNDS FOR TREATING ACUTE INFLAMMATION | TES PHARMA S.R.L. (IT) | 2023-11-30 | — | — | WO | disclosed |
| US-11254644-B2 | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase | TES PHARMA S.R.L. (IT) | 2022-02-22 | — | — | US | disclosed |
| EP-3186242-B1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S R L (IT) | 2021-10-06 | — | — | EP | disclosed |
| US-20200207721-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S.R.L. (IT) | 2020-07-02 | — | — | US | disclosed |
| US-20170362185-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S.R.L. (IT) | 2017-12-21 | — | — | US | disclosed |
| US-9708272-B2 | Inhibitors of α-amino-β-carboxymuconic acid semialdehyde decarboxylase | TES PHARMA S.R.L. (IT) | 2017-07-18 | — | — | US | disclosed |
| US-9708272-B2 | Inhibitors of α-amino-β-carboxymuconic acid semialdehyde decarboxylase | TES PHARMA S.R.L. (IT) | 2017-07-18 | — | — | US | disclosed |
| US-20160060226-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S.R.L. (IT) | 2016-03-03 | — | — | US | disclosed |
| US-20160060226-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S.R.L. (IT) | 2016-03-03 | — | — | US | disclosed |
| WO-2016030534-A1 | INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S.R.L. (IT) | 2016-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200207721-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | ACMSD, GLS, ALDH7A1 | ACMSD 1/4885CYP2C19 1550/4885MEN1 2572/4885 |
| US-20160060226-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | ACMSD, GLS, ALDH7A1 | ACMSD 1/4885CYP2C19 1550/4885MEN1 2572/4885 |
| US-20170362185-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | ACMSD, GLS, ALDH7A1 | ACMSD 1/4885CYP2C19 1550/4885MEN1 2572/4885 |
| US-11254644-B2 | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase | ACMSD, GLS, ALDH7A1 | ACMSD 1/4885CYP2C19 1550/4885MEN1 2572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.